Clinical Trial Details
| Trial ID: | L7143 |
| Source ID: | NCT01369277 |
| Associated Drug: | Pf-04991532 |
| Title: | A Single Dose Study In Japanese And Western Healthy Subjects To Investigate The Safety, Tolerability And Pharmacokinetics Of PF-04991532 |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes Mellitus|Diabetes Mellitus, Type 2|Glucose Metabolism Disorders |
| Interventions: | DRUG: PF-04991532|DRUG: Placebo|DRUG: PF-04991532 |
| Outcome Measures: | Primary: Maximum Plasma Concentration (Cmax), Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12 and 16, 24, 36 and 48 hours post dose|Time for Cmax (Tmax), Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12 and 16, 24, 36 and 48 hours|Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast), Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12 and 16, 24, 36 and 48 hours|Area under the plasma concentration-time profile from time zero to 24 hours (AUC0-24), Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10,12 and 16, 24, 36 and 48 hours|Total amount of unchanged drug excreted in the urine over 24 hours, expressed as percent of dose (Ae24%), Urine collection from 0 to 24 hours post dose|Renal clearance (CLr), Urine collection from 0 to 24 hours post dose | |
| Sponsor/Collaborators: | Sponsor: Pfizer |
| Gender: | ALL |
| Age: | ADULT |
| Phases: | PHASE1 |
| Enrollment: | 22 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: |
| Start Date: | 2011-06 |
| Completion Date: | 2011-09 |
| Results First Posted: | |
| Last Update Posted: | 2011-09-22 |
| Locations: | Pfizer Investigational Site, New Haven, Connecticut, 06511, United States |
| URL: | https://clinicaltrials.gov/show/NCT01369277 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|